cryptosporidiosi
caus
lifethreaten
diarrhea
infant
best
avail
treatment
modestli
efficaci
rodent
infect
relev
cryptosporidium
speci
develop
diarrhea
complic
drug
develop
cryptosporidium
parvum
infect
dairi
calv
howev
caus
ill
like
seen
infant
clinic
microbiolog
anticryptosporidium
efficaci
piperazinebas
compound
demonstr
neonat
calv
oral
administr
mgkg
daili
begun
two
day
onset
sever
diarrhea
continu
seven
day
treatment
result
prompt
resolut
diarrhea
reduc
total
fecal
oocyst
shed
use
treatment
rather
prophylaxi
sinc
safe
effect
administ
well
onset
diarrhea
furthermor
even
though
anim
receiv
intens
support
care
strong
trend
toward
improv
secondari
health
outcom
includ
gener
health
appetit
dehydr
measur
amongst
treat
anim
data
establish
outstand
lead
compound
cryptosporidium
drug
develop
diarrhea
still
caus
childhood
death
although
cryptosporidiosi
previous
recogn
major
contributor
diarrhea
endem
area
recent
multicent
studi
africa
asia
found
cryptosporidium
infect
mostli
due
cryptosporidium
homini
cryptosporidium
parvum
third
common
caus
sever
diarrhea
young
children
cryptosporidium
infect
also
strongli
associ
malnutrit
delay
develop
furthermor
cryptosporidiosi
preval
caus
chronic
diarrhea
aid
patient
respons
waterborn
diarrhea
outbreak
unit
state
treatment
cryptosporidiosi
affect
popul
poor
nitazoxanid
drug
proven
efficaci
immunocompet
peopl
shorten
ill
approxim
one
day
nitazoxanid
equival
placebo
hiv
posit
peopl
data
young
malnourish
children
come
studi
children
nitazoxanid
recipi
improv
seven
day
placebo
recipi
improv
dire
need
develop
effect
treatment
peopl
cryptosporidiosi
cryptosporidium
parvum
infect
calv
econom
concern
beef
milk
produc
may
contribut
contamin
water
suppli
human
diseas
outbreak
nationwid
survey
us
farm
cryptosporidium
present
farm
infect
calv
age
week
although
outbreak
human
cryptosporidiosi
due
anthroponot
transmiss
human
restrict
isol
zoonot
transmiss
livestock
associ
isol
caus
larg
outbreak
control
cryptosporidiosi
calv
would
therefor
econom
benefit
reduc
burden
human
diseas
other
previous
use
cellbas
assay
identifi
potenti
cryptosporidium
drug
lead
combin
followup
vivo
studi
immunocompromis
mice
one
promis
compound
found
date
identifi
within
medicin
malaria
ventur
malaria
box
open
access
collect
compound
activ
erythrocyt
stage
plasmodium
falciparum
piperazinebas
compound
high
select
blood
stage
malaria
parasit
cryptosporidium
speci
potenc
roughli
equival
multipl
c
parvum
lab
field
isol
c
homini
isol
treatment
reduc
parasit
shed
detect
limit
highli
immunocompromis
mous
model
chronic
c
parvum
infect
jumani
et
al
submit
manuscript
limit
exist
mous
cryptosporidiosi
model
howev
infect
mice
develop
diarrhea
thu
proven
microbiolog
efficaci
immunocompromis
mice
clinic
efficaci
treat
cryptosporidiosi
remain
unknown
neonat
calv
infect
c
parvum
shed
oocyst
high
level
develop
diarrhea
similar
seen
young
children
provid
clinic
model
drug
test
studi
purpos
determin
clinic
microbiolog
efficaci
dairi
calv
report
pharmacokinet
pk
data
uninfect
calv
infect
calv
diarrhea
result
clinic
efficaci
studi
within
two
hour
birth
transport
uvm
uninfect
anim
grouphous
pen
pk
studi
studi
infect
calv
anim
initi
grouphous
infect
hour
age
interrupt
bottl
feed
oral
administr
viabl
c
parvum
iowa
isol
oocyst
bunch
grass
farm
deari
id
suspend
ml
deioniz
water
anim
move
individu
rais
pen
immedi
infect
observ
twice
daili
feed
time
clinic
sign
quantifi
accord
standard
score
rubric
tabl
fecal
consist
gener
health
hydrat
statu
appetit
data
collect
clinic
microbiolog
studi
adventiti
infecti
agent
includ
salmonella
cultur
aerob
bacteri
cultur
e
coli
genotyp
rotaviru
coronaviru
test
perform
calv
onset
diarrhea
cornel
health
diagnost
center
ithaca
ny
anim
sever
diarrhea
symptom
support
aggress
includ
administr
oral
electrolyt
intraven
fluid
flunixin
meglumin
banamin
merck
need
suspend
dose
hydroxypropyl
methylcellulos
water
final
volum
ml
per
dose
dose
squirt
calv
mouth
interrupt
bottl
feed
pk
studi
fecal
sampl
collect
indic
time
manual
anal
stimul
treatment
efficaci
studi
daili
fecal
sampl
obtain
collect
bin
locat
pen
fecal
sampl
use
parasit
quantif
dri
stabl
weight
reach
c
parvum
abund
per
gram
fecal
dri
matter
measur
use
previous
valid
qpcr
assay
knowledg
qpcr
assay
sensit
method
current
avail
lower
limit
detect
oocystsgram
dri
fece
serum
sampl
analyz
liquid
chromatographytandem
mass
spectrometri
lcm
ms
use
compound
spike
control
serum
standard
fecal
measur
homogen
fece
pb
gml
polypropylen
tube
dilut
prior
addit
intern
standard
enalapril
acetonitril
protein
precipit
supernat
transfer
fresh
tube
dri
use
speed
vac
sampl
resuspend
analyz
use
lcmsm
data
analyz
use
graphpad
prism
version
area
curv
auc
calcul
anim
use
plot
indic
paramet
vs
time
baselin
score
one
ie
calf
score
one
everi
day
diarrhea
would
auc
auc
oocyst
shed
determin
plot
log
transform
fecal
oocyst
shed
per
gram
fecal
dri
matter
vs
time
use
baselin
log
includ
first
day
drug
dose
p
valu
determin
use
unpair
oneway
student
test
graph
label
fig
prepar
use
adob
illustr
remain
unknown
intestin
system
compound
concentr
requir
vivo
efficaci
achiev
total
sustain
serum
concentr
ec
immunocompromis
mous
model
previous
reduc
parasit
detect
level
mice
treat
lower
dose
quickli
relaps
jumani
et
al
submit
manuscript
determin
compar
dose
regimen
clinic
efficaci
studi
calf
model
therefor
began
experi
uninfect
anim
receiv
singl
oral
dose
follow
measur
serum
fecal
compound
concentr
fig
total
serum
concentr
exceed
target
concentr
ec
within
hour
receipt
mgkg
oral
level
persist
hour
fecal
concentr
exceed
ec
two
hour
persist
hour
data
suggest
possibl
efficaci
use
daili
dose
mgkg
remain
possibl
diarrhea
cryptosporidium
infect
calv
would
alter
pk
profil
conduct
pilot
studi
infect
anim
use
mgkg
daili
administ
seven
day
begin
day
four
postinfect
two
day
onset
sever
diarrhea
fig
dose
result
sustain
fecal
serum
concentr
excess
target
concentr
also
appear
safe
well
toler
dose
sinc
advers
effect
tast
avers
note
next
test
clinic
microbiolog
efficaci
treatment
cryptosporidiosi
use
calf
model
neonat
bull
calv
infect
oral
administr
c
parvum
iowa
isol
oocyst
high
inoculum
use
consist
result
infect
onset
sever
hour
administr
fig
infect
calv
receiv
either
mgkg
daili
seven
day
vehicl
alon
neg
control
begin
day
four
infect
time
point
correspond
second
day
sever
diarrhea
treatment
reduc
diarrhea
sever
within
one
day
fig
correspond
two
log
reduct
number
oocyst
per
gram
fecal
dri
matter
within
two
day
begin
treatment
fig
interestingli
low
level
oocyst
shed
continu
despit
ongo
treatment
complet
resolut
diarrhea
consist
prior
observ
natur
histori
cryptosporidium
infect
dairi
calv
demonstr
persist
low
level
oocyst
shed
resolut
ill
observ
day
follow
infect
fig
treatment
reduc
sever
diarrhea
number
oocyst
shed
auc
anim
calcul
plot
fecal
consist
vs
time
includ
first
day
drug
dose
use
quantifi
magnitud
reduct
diarrhea
cours
studi
consist
gener
clinic
observ
caregiv
treatment
dramat
reduc
number
anim
day
moderatetosever
diarrhea
fig
similarli
calcul
auc
log
transform
oocyst
shed
anim
demonstr
treatment
reduc
overal
shed
geometr
mean
total
oocyst
shed
vs
treat
vs
control
despit
delay
treatment
peak
diarrhea
fig
effect
treatment
overal
health
dehydr
appetit
c
parvum
infect
calv
quantifi
use
standard
score
system
tabl
calcul
auc
paramet
calv
receiv
aggress
support
care
attempt
mitig
unnecessari
suffer
limit
magnitud
differ
might
observ
experiment
group
nonetheless
strong
trend
toward
improv
health
treatment
assess
secondari
clinic
outcom
measur
fig
studi
valid
efficaci
piperazinebas
anticryptosporidium
drug
lead
clinic
model
diseas
critic
extens
previou
mous
studi
mice
infect
c
parvum
develop
diarrhea
dairi
calv
hand
develop
diarrheal
ill
similar
observ
infant
follow
infect
c
parvum
one
two
main
human
pathogen
data
show
clinic
microbiolog
effect
treatment
cryptosporidiosi
newborn
calv
sinc
c
parvum
also
import
pathogen
cattl
data
repres
key
step
drug
develop
direct
toward
treatment
calv
peopl
afflict
cryptosporidiosi
provid
strong
rational
optim
piperazinebas
chemotyp
somewhat
surpris
diarrhea
reduc
fecal
serum
concentr
follow
oral
administr
may
simplifi
dose
optim
final
note
method
use
studi
hous
calv
confin
pen
stress
anim
therefor
like
immunosuppress
emphas
clinic
efficaci
studi
sever
limit
recent
publish
target
product
profil
anticryptosporidium
drug
specifi
typic
treatment
durat
day
patient
sever
immunocompromis
patient
may
requir
prolong
treatment
thu
addit
studi
need
determin
minimum
durat
efficaci
also
bull
includ
due
limit
access
heifer
studi
need
address
possibl
sex
differ
efficaci
despit
prior
studi
demonstr
compar
vitro
potenc
c
parvum
c
homini
isol
jumani
et
al
submit
manuscript
confirm
vivo
efficaci
c
homini
also
need
eg
use
gnotobiot
piglet
model
although
toxic
anim
observ
vitro
patch
clamp
studi
demonstr
partial
inhibit
human
etheragogo
herg
potassium
channel
physiolog
relev
concentr
indic
possibl
cardiac
toxic
addit
safeti
studi
therefor
need
assess
possibl
cardiotox
medicin
chemistri
optim
increas
potenc
select
like
warrant
although
optim
pharmacokinet
properti
seri
eg
high
vs
low
system
bioavail
remain
determin
also
possibl
herg
liabil
address
modif
result
lower
oral
absorpt
case
medicin
chemistri
optim
would
like
aid
knowledg
molecular
mechan
remain
unknown
cryptosporidium
plasmodium
speci
nonetheless
base
outstand
clinic
microbiolog
efficaci
rel
eas
synthes
relat
compound
repres
excel
start
point
fullfledg
anticryptosporidium
drug
lead
optim
program
support
inform
fig
natur
histori
c
parvum
dairi
calf
infect
use
protocol
studi
calv
infect
hour
age
oral
administr
c
parvum
iowa
isol
oocyst
fecal
oocyst
shed
follow
use
qpcr
graph
show
fecal
oocyst
shed
vs
time
dash
line
indic
reliabl
limit
detect
lod
qpcr
assay
data
mean
sem
log
oocystsgram
fecal
dri
matter
n
calv
ep
